FDA approves electric headband to prevent migraine

The U.S. Food and Drug Administration said Tuesday it approved a Belgium-made nerve-stimulating headband as the first medical device to prevent migraine headaches.

Agency officials said the device provides a new option for patients who cannot tolerate migraine medications.

The Cefaly device is a battery-powered plastic band worn across the forehead. Using an adhesive electrode, the band emits a low electrical current to stimulate nerves associated with migraine pain. Users may feel a tingling sensation on the skin where the electrode is applied. The device is designed to be used no more than 20 minutes a day by patients 18 years and older.

A 67-person study reviewed by the FDA showed patients using the device experienced fewer migraines per month than patients using a placebo device. The Cefaly headband did not completely eliminate migraine headaches or reduce the intensity of migraines that occurred.

About 53 percent of 2,313 patients in a separate study said they were satisfied with the device and were willing to purchase it for future use.

No serious adverse events were connected with the device.

Cephaly is manufactured by Cephaly Technology of Belgium.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

FDA approves new magnet device to treat migraines

Dec 15, 2013

(HealthDay)—The U.S. Food and Drug Administration has approved the first device aimed at easing the pain of migraines preceded by aura—sensory disturbances that occur just before an attack.

Hand-held device may prevent migraine

Mar 05, 2010

(PhysOrg.com) -- A new portable device that delivers a magnetic pulse to the back of the head could prevent or treat migraines in people susceptible to them.

Recommended for you

Xtoro approved for swimmer's ear

12 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

12 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.